Informasjon/Twitter/Artikler/Børsmeldinger


Jeg vet at mange har interesse av å følge med på utviklingen i Photocure. Og for dem som eventuelt ikke er medlem i vår Facebook gruppe skal jeg også publisere her innimellom. Dersom dere ønsker å diskutere noe av det som blir delt her kan dere gjøre det på andre tråder.
Erfaringsmessig blir enhver PHO tråd ødelagt ganske umiddelbart så jeg holder den åpen kun for lesetilgang.
Forøvrig er dere hjertelig velkommen inn i FB gruppen som nå teller hele 599 medlemmer.
Det finnes 3273 aksjonærer i Photocure så det er plass til flere i gruppen.

Starter med et lite utvalg av delingene på fb gruppen siste uken.

PS! FB gruppen har nå 785 medlemmer!, den 22.8. 30.9 har den 814. og 20.11 har den 878 medlemmer.


https://twitter.com/Cysview/status/1139565681874223105

http://santansun.com/2019/06/13/gilberts-md-anderson-center-celebrates-survivors/?fbclid=IwAR3w248nRjxHfZ8Zb1C9-FGAEJL4vIXLTMbOADei7oIoHooB4SIJUwZzcIU

https://www.youtube.com/watch?v=AQCSH005uDs&fbclid=IwAR1M0zvb7he1ikyc7U6Bor3T4Tjhf1BfLkJJmnL7myLQdFzM8CM0o-qV9M0

https://finance.yahoo.com/news/why-photocure-asa-ob-pho-120355805.html?guce_referrer=aHR0cHM6Ly90ZWtpbnZlc3Rvci5uby8&guce_referrer_sig=AQAAAN1bXZLFh3xYZBPzMKtz4JpEyTxNURdI7tWOsZyP8CcFouBFik2iBwjFLBhuAduKZ4xjJpIbGqQ7lZspb9lLvZ44wdtmZhik79grZWWYVAD5SvQ1v2rfqCbtGOH5nSHLiqcRFSlOolw2BHh2m1B-keblOZk2OMtU0Nd73tCD2OzZ&guccounter=2

https://www.sciencedirect.com/topics/medicine-and-dentistry/cystoscopy?fbclid=IwAR3W1N0UZMYb4zVQ_0X2S3G4X46NYqA53ShEqAzvTZLo7qfdDALItsApCvM

https://www.mdlinx.com/journal-summaries/urothelial-carcinoma-in-situ-blue-light/2019/06/10/7569052/?spec=urology&fbclid=IwAR2xAB2LFKvvOIHC0h2zuSOrH50pHGXCJDV5hpq_66RZlXYp6eK3QUBLMR8

https://twitter.com/PhotocureASA/status/1138507513077403649

https://www.bcan.org/wp-content/uploads/2019/06/Recurrence-and-Prevention-Transcript.pdf?fbclid=IwAR3IkuPa34ZCxtyBA5LBZRlPBQvfhtz_T3UsynZx_ARWvJ2sQChY05Aqz14


Redigert 20.11.2019 kl 17:12 Du må logge inn for å svare

For bladder cancer detection, the urologists are the first in central Connecticut to use a new blue light cystoscopy technology to illuminate tumors in the bladder and identify smaller cancers earlier than ever before.

Certain tumors are hard to detect using traditional white light cystoscopy, but turn pink under the enhanced imaging provided by the blue light.

“Recurrence rates for bladder cancers are somewhere in the 50–70% range. Using blue light cystoscopy, depending on the tumor type, can reduce the risk of recurrence by about 40%, which means fewer trips to the operating room,” says Dr. Benjamin Ristau, UConn Health’s surgical director of urologic oncology.

https://twitter.com/UConn/status/1186666022692098048?s=20
Redigert 22.10.2019 kl 19:53 Du må logge inn for å svare

Klinikk nummer 138 lagt til på Cysview.
Ronald Reagan UCLA Medical Center

The Ronald Reagan UCLA Medical Center (also commonly referred to as UCLA Medical Center or "RRMC") is a hospital located on the campus of the University of California, Los Angeles, in Westwood, Los Angeles, California, United States. It is currently ranked the 6th best hospital in the United States by U.S. News & World Report, and 1st in the West Coast.[2]
Redigert 23.10.2019 kl 06:44 Du må logge inn for å svare

Nå går det jaggu unna i USA!

Klinikk nummer 139, 140 og 141 oppført på Cysview.

Capital Health Medical Center - Hopewell

1 Capital Way Pennington, NJ 08534

Capital Health – Urology Specialists

1050 Stony Hill Road Yardley, PA 19067

Capital Health – Urology Specialists

Two Capital Way, Suite 407 Pennington, NJ 08534

Kom plutselig over denne store studien som skal avsluttes i 2020.
Har selv aldri sett dette før, kanskje flere enn undertegnede som gjerne vil se.

https://ichgcp.net/clinical-trials-registry/NCT02660645?fbclid=IwAR0iSkilDn45b63ryQvV6fj1D28oGIozd_R-pfVOG4Fs6xnFKo-bb9sdu6M

Da er er den første av to konferanser denne helgen og neste uke igang.
Har ikke lest programmet, men antar at Pho deltar direkte eller indirekte siden selskapet er nevnt:

Thank you
2019 Exhibitors
Photocure
https://whova.com/web/wsaua_201911/#exhibitor

https://drive.google.com/file/d/1ssbvPOCb188MLGM4hVRNntB-hv9uqras/view
https://drive.google.com/file/d/1JdSuy693OtiorEsPOUcIh8dwHJOq2sof/view

https://monterey19.wsaua.org/
Redigert 02.11.2019 kl 12:56 Du må logge inn for å svare

Jeg ser virkelig fram til svaret på deres spørsmål:
"Kan det norske selskapet bli monopolist globalt på diagnostikk og behandling av blærekreft?"

Programmet for podcasten:
Podkast 100 - live fra Kulturhuset torsdag 7. november.
Program er nå klart:
15:00 - 15:15: Mingling med god mat og drikke
15:15 - 15:45: Daniel Schneider, CEO Photocure:
> "Kan det norske selskapet bli monopolist globalt på diagnostikk og behandling av blærekreft?"
15:45 - 16:15: Torbjørn Furuseth, CFO Targovax:
“Er kombinasjonen av onkolytisk virus og sjekkpunkthemmer det som skal til for å få fart på effekten av immunterapi?”
16:15 - 16:45: Kari Grønås, lungekreftpasient og tidligere del av toppledelsen i Algeta, og Kjetil Taskén, leder for Institutt for Kreftforskning ved Oslo universitetssykehus:
“Kreftbehandling i dag og i framtiden - hva kan vi forvente oss?”
16:45 - 18:00 - Mer mat & mingling og godt drikke
Håper du kommer!

En ny strålende artikkel om BLC fra Marcus Daly Memorial Hospital.

Deler ikke linken da denne ikke virker for oss her til lands, her derfor fått tak i den direkte fra utgiver, Ravalli Republic | Montana and Bitterroot Valley News

A new urologist at Marcus Daly Memorial Hospital has been rapidly uncovering types of cancer in the Bitterroot Valley.

Kellan Clark, Doctor of Osteopathic Medicine, started in August and said the need for full-time urology services in the valley is obvious.

“We’re currently booking office appointments out to December and we’re booking surgeries well into November,” Dr. Clark said. “We save appointments for acute needs and need to save more. The ER here is quite busy with urology issues.”

From a urology standpoint, the aging population and general problems of urinary retention has been a significant part of Dr. Clark’s practice. He’s also seen a significant amount of kidney stones.

He said that in regards to cancer, in two months he has diagnosed more prostate cancer and bladder cancer than he expected.

He said the new technology is extremely valuable and with the bladder cancer. The Blue Light Cystoscopy with Cysview has proven to be effective in the cases he has used it on.

“With this technology we were finding small tumors that I otherwise wouldn’t have been able to see,” Dr. Clark said. “That has been really helpful.

“Cysview is basically a substance that you insert into the bladder with a catheter one hour before surgeryand it attaches to cancer cells within the bladder,” Dr. Clark said. “Then when you flip on the blue light with a special scope, the cancer within the bladder turns up as a bright pink, with the rest of the bladder being a blue or purplish color.”

He said, the benefit of that technology is that he can see small tumors just starting to form that he couldn’t see with the normal white light.

“Bladder cancer is a disease that is recurrent. Fifty to 60% of patients will have recurrence of what we call ‘Ta’ (a stage of a tumor) or superficial bladder cancer,” Dr. Clark said. “So, when you can find these future recurrences as they are developing then you potentially offer the patient a longer interval between treatments, a longer interval between recurrences.”

The typical course of bladder cancer is a patient would come in with complaints of symptoms of irritation or blood in their urine.

“We would perform a Cystoscopy here in the office where we would look at the bladder with a scope,” Dr. Clark said. “Then we might see a tumor. When we see a tumor the patient goes to the operating room and I go in with special equipment that resects the tumor from inside the bladder. Then you get that specimen to the lab to see if it is low grade or high grade tumor and how invasive it is.”

The results from that resection determine the next course of treatment.

“It is usually when I resect the tumor that I use the Blue Light Cystoscopy to evaluate for any other lesions that I might not be able to see otherwise,” Dr. Clark said.

In the future he may do the blue light Cystoscopy in the office just for screening purposes.

Dr. Clark recommends having symptoms checked. Blood in the urine (that you can see or detected in a “microscopic” urine test), urinary frequency, urinary urgency or a sudden change in urinary habits and irritating voiding symptoms.

“If you see blood in the urine, call me,” Dr. Clark said.

Having Blue Light Cystoscopy available locally is a major asset for the community. Marcus Daly Memorial Hospital has been the only place with it available in the northwest until recently.

“I used it pretty heavily in my training on the East Coast and I was quite surprised that there was no one in Montana, Idaho, Washington or Oregon that was doing it, until Portland recently started using it,” Dr. Clark said.

He said that often hospitals take their time before embracing new technology.

“But here I just said, ‘I think it is good for patient care, I’ve used it in the past and I’d like to bring it here’ and they said ‘sure,’” he said.

There is the potential that patients may start coming here from out-of-state for Blue Light Cystoscopy.

“It’s a tremendous service, and new technology, for a troublesome disease such as bladder cancer,” Dr. Clark said.

The rescreening timetable is different for all patients, dependent on how fast the tumor is growing and other variables.

“They have to typically come back for screening Cystoscopies after their bladder cancer has been treated, at least every six months for a few years, then annually,” Dr. Clark said. “Bladder cancer is a burdensome disease on the patient even once it has been treated. You still have surveillance and the best way is with Cystoscopies.”

Dr. Clark said Blue Light Cystoscopies have proven to be “very helpful” in cases here in the Bitterroot Valley.

“They would have probably shown up three months later, but you can see the benefit of finding those lesions early – it is fewer trips to the operating room for the patient,” he said. “Outside of skin cancer, prostate cancer is the most common cancer among men. Accordingly, I’ve diagnosed a lot more prostate cancer than bladder cancer since I’ve been here.”

Screening for prostate cancer is based off of Prostate-specific antigen (PSA) testing and rectal exams.

“The current American Urology Association (AUA) guidelines say that any man at risk for prostate cancer should have a PSA every year or every other year from age 55 to 70, and those men should also have a rectal exam, annually, for prostate cancer screening,” Dr. Clark said. “Further PSA monitoring or screening after the age 70 is then based on patient preference and their discussion with their physician.”

Similar to the need for mammograms, Dr. Clark said he sees the need for continual PSA testing.

“There are significant limitations with PSA tests but you look at not just one single number but at the trend,” Dr. Clark said. “If the PSA remains elevated over multiple occasions then the next step is a prostate biopsy to rule out prostate cancer.”

Dr. Clark said he conducts his prostate biopsies “transperineal,” with two small poke holes below the scrotum.

“The infection risk is almost completely zero and I feel it feels like it provides better biopsy samples,” he said. “I feel very strongly about that.”

Fikk denne på mail fra Cysview for 2 timer siden, trodde den var delt tidligere, men nå ble jeg sannelig i tvil.

Video on UroToday.com
Features Bladder Cancer Thought Leader Discussion
of Patient Types for Blue Light Cystoscopy with Cysview®

In a presentation published on UroToday.com called Consensus Statement on Flexible Blue-Light Cystoscopy (BLC™) with CYSVIEW, Dr. Yair Lotan discusses the results of a consensus meeting of 17 bladder cancer experts. These experts published their recommendations about the appropriate patient types for using Blue Light Cystoscopy (BLC™) with Cysview in the clinic setting.

With the growing popularity of using Blue Light Cystoscopy with Cysview in the clinic to detect bladder cancer, determine response to therapy, and detect residual disease, these consensus opinions help define who should get it.

https://www.urotoday.com/video-lectures/bladder-cancer-special-session-eau-2019/video/mediaitem/1266-embedded-media2019-04-19-16-06-51.html

Hyggelig å registrere at CEO Dan Schneider avlegger hovedstaden et besøk igjen i desember. Han holder innlegg på DNB Nordic Healtcare Konferansen torsdag 12.desember.

http://dnb.meetmax.com/sched/event_58613/__agenda_cp.html?fbclid=IwAR2lGaGXtNJVVoMJvHqrdM6RMrfz-a8TK2k4lIjhV-65tLLHdoLvp0WV_BY

Klinikk nummer 142 lagt til på Cysview.
University of Virginia Department of Urology

Urologic surgeon Zachary Smith, MD, discusses a new technology for improved detection of bladder cancer called Blue Light Cystoscopy, which “enables us to more easily find and diagnose tumors.” Read how this technology is a “huge win for our patients.”

https://twitter.com/WashUSurgery/status/1198992259628326912?s=20

Klinikk nummer 143 oppført på Cysview.
Memorial Sloan Kettering Cancer Center
1275 York Ave, New York, NY 10065

Tydelig at markedsandeler skal tas i USA nå.
Ytterligere 2 nye stillinger utlyst denne uken.

https://photocure.com/careers/vacancies-united-states/

Blue Light Cystoscopy fra 53 min. Dette er en ny video fra 21st Century Methods of Detecting Urological Cancers
Milford Regional Medical Center.
Denne klinikken ble oppført på Cysview 29 mai.

https://www.youtube.com/watch?v=fsuiVQBUcn4
Redigert 27.11.2019 kl 20:27 Du må logge inn for å svare

Hentet ut en ny Topp 20 liste gjeldende til og med torsdag i forrige uke.

JP Morgan Securities 186,214 aksjer NY på Topp 20(17.plass)

Ellers små justeringer. Fondene har redusert med mindre poster, mens enkelte andre har økt med små poster.

20.plassen innehas nå av Lehre Holding med 164,390 aksjer.

Har hentet ut liste gjeldende til og med fredag i forrige uke, små endringer, men JP Morgan Securities skiller seg ut positivt.
Fra 186,000 aksjer på torsdag til over 210,000 på fredag og hopper fra 17.plass til 14.plass.